

Regimen Reference Order – LYMP – riTUXimab desensitization

riTUXimab desensitization protocol is prescribed in combination with a riTUXimab-based protocol

Planned Course: Refer to prescribed riTUXimab-based protocol

Indication for Use: Eligible patients with Grade 3 or 4 infusion reactions to riTUXimab

CVAD: Refer to prescribed riTUXimab-based protocol

Proceed with treatment if:

❖ Refer to prescribed riTUXimab-based protocol

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed riTUXimab-based protocol</i>		

Treatment Regimen – LYMP – riTUXimab desensitization

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
acetaminophen	650 mg	Orally 45 minutes prior to riTUXimab
dexamethasone	20 to 40 mg	IV in normal saline 50 mL over 15 minutes 45 minutes prior to riTUXimab
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes 30 minutes prior to riTUXimab
raNITidine	50 mg	IV in normal saline 50 mL over 15 minutes 30 minutes prior to riTUXimab <i>*Nursing Alert: riTUXimab starts 30 minutes after completion of diphenhydrAMINE and raNITidine</i>
riTUXimab (brand name specific)	375 mg/m ²	IV in normal saline made up to a final concentration of 1 mg/mL following the administration rates below: Step 1: 2 mL/hour for 15 minutes, then Step 2: 4 mL/hour 15 minutes, then Step 3: 6 mL/hour for 15 minutes, then Step 4: 8 mL/hour for 15 minutes, then Step 5: 10 mL/hour 15 minutes, then Step 6: 15 mL/hour for 15 minutes, then Step 7: 30 mL/hour for 15 minutes, then Step 8: 60 mL/hour for 15 minutes, then give diphenhydrAMINE <i>*Nursing Alert: There is no interruption in riTUXimab infusion unless patient is experiencing an infusion-related reaction</i>

diphenhydrAMINE	25 mg	Orally immediately prior to Step 9 during riTUXimab infusion
riTUXimab (brand name specific) Continued from above		<p>Step 9: 80 mL/hour for 15 minutes, then</p> <p>Step 10: 100 mL/hour for 15 minutes, then</p> <p>Step 11: 120 mL/hour for 15 minutes, then</p> <p>Step 12: 140 mL/hour for 15 minutes, then</p> <p>Step 13: 160 mL/hour for 15 minutes, then</p> <p>Step 14: 180 mL/hour for 15 minutes, then</p> <p>Step 15: 200 mL/hour until infusion is complete</p> <p><i>*Nursing Alert: IV tubing is primed with riTUXimab</i></p> <p><i>*Alert: Pharmacy to ensure final volume on label</i></p> <p><i>*Alert: riTUXimab must be the first agent administered when given in combination with another chemotherapy agent</i></p> <p><i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i></p>

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) prior to each riTUXimab infusion and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they have had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
<i>Refer to the prescribed riTUXimab-based protocol</i>		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Refer to prescribed riTUXimab-based protocol for additional discharge instructions

ADDITIONAL INFORMATION

- Once the patient requires riTUXimab desensitization protocol, all subsequent riTUXimab doses **must be given using riTUXimab desensitization protocol**
- Hematologist must write first prescription of riTUXimab desensitization protocol
- Administering nurse must document any infusion-related reactions with any dose of riTUXimab
- Refer to the prescribed riTUXimab-based protocol for additional riTUXimab information
- Due to the duration of treatment, administration site restrictions may be in place
- Intravenous riTUXimab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after riTUXimab. **Ensure prescription label matches the brand name on prescribed order**